In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 John J V McMurray
Speaker
John J V McMurray
John J V McMurray John J V McMurray

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

Specialities : Acute Heart Failure , Acute Heart Failure, Atrial Fibrillation

108 presentations from this speaker

Changing the outlook for a heart failure patient leaving the hospital

Event : ESC Congress 2019

  • Session : Heart failure treatment - Keeping the patient on the top of our mind
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

DAPA HF - The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

Event : ESC Congress 2019

  • Session : Meet the trialist - DAPA-HF
  • Speaker : JJV McMurray (Glasgow,GB)

DAPA HF - The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

Event : ESC Congress 2019

  • Session : Hot Line Session 1
  • Speaker : JJV McMurray (Glasgow,GB)

Discussions, questions and answers

Event : ESC Congress 2019

  • Session : Heart failure treatment - Keeping the patient on the top of our mind
  • Speaker : JJV McMurray (Glasgow,GB), A Mebazaa (Paris,FR), J Januzzi (Boston,US)
  • Sponsored by Novartis Pharma AG

Discussions, questions and answers

Event : ESC Congress 2019

  • Session : Treating patients with HFpEF: what progress are we making?
  • Speaker : CS Lam (Singapore,SG), JJV McMurray (Glasgow,GB), S Solomon (Boston,US)
  • Sponsored by Novartis Pharma AG

Experts debate - Challenges faced in diagnosing and managing HFpEF.

Event : Heart Failure 2019

  • Session : Challenges faced in diagnosing and managing HFpEF
  • Speaker : CS Lam (Singapore,SG), JJV McMurray (Glasgow,GB), B Pieske (Berlin,DE), L Lund (Stockholm,SE), A Voors (Groningen,NL)
  • Organised by Medscape Education, supported with an educational grant from Novartis

Heart failure & diabetes: what is the goal of treatment?

Event : Heart Failure 2019

  • Session : Reshaping the future of heart failure management - Translating innovations to practice in HFpEF
  • Speaker : JJV McMurray (Glasgow,GB)
  • Organised by PACE-CME - Physicians' Academy for Cardiovascular Education, supported with educational grants provided by Novartis, Novo Nordisk and Pfizer

How well do you know HFpEF? Meet the experts

Event : ESC Congress 2019

  • Session : How well do you know HFpEF? Meet the experts
  • Speaker : L Lund (Stockholm,SE), JJV McMurray (Glasgow,GB), S Solomon (Boston,US)
  • Organised by Medscape Education, supported with an independent grant from Novartis Pharma AG

Is HFpEF the largest unmet need in cardiology?

Event : ESC Congress 2019

  • Session : Treating patients with HFpEF: what progress are we making?
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

Messages from recent trials in HFpEF

Event : ESC Congress 2019

  • Session : New hope for HFpEF patients
  • Speaker : JJV McMurray (Glasgow,GB)

Panel discussion

Event : Heart Failure 2019

  • Session : Meet the experts on getting to grips with HFpEF
  • Speaker : JJV McMurray (Glasgow,GB)
  • Organised by Medscape Education, supported with an educational grant from Novartis

Panel discussion - Making critical choices for patients at the right time.

Event : Heart Failure 2019

  • Session : Making critical choices for patients at the right time – Join the discussion
  • Speaker : F Ruschitzka (Zurich,CH), JJV McMurray (Glasgow,GB), M Senni (Bergamo,IT), J Butler (Atlanta,US)
  • Sponsored by Novartis

Panel discussion - Treatment choices to optimise benefits for heart failure patients.

Event : Heart Failure 2019

  • Session : Treatment choices to optimise benefits for heart failure patients
  • Speaker : F Ruschitzka (Zurich,CH), JJV McMurray (Glasgow,GB), M Senni (Bergamo,IT), J Butler (Atlanta,US)
  • Sponsored by Novartis

Personalising care for heart failure patients.

Event : Heart Failure 2019

  • Session : Treatment choices to optimise benefits for heart failure patients
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis

Summary and conclusion - Treatment choices to optimise benefits for heart failure patients.

Event : Heart Failure 2019

  • Session : Treatment choices to optimise benefits for heart failure patients
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis

The ABCs of HFpEF and pitfalls in diagnosis

Event : ESC Congress 2019

  • Session : The heart failure challenge: how well do you know HFpEF?
  • Speaker : JJV McMurray (Glasgow,GB)
  • Organised by Medscape Education, supported with an independent grant from Novartis Pharma AG

The cardiologist perspective on GLP-1 receptor agonist and DPP-4 inhibitors.

Event : Heart Failure 2019

  • Session : Focus on diabetes in heart failure
  • Speaker : JJV McMurray (Glasgow,GB)

Welcome and faculty introductions

Event : Heart Failure 2019

  • Session : Meet the experts on getting to grips with HFpEF
  • Speaker : JJV McMurray (Glasgow,GB)
  • Organised by Medscape Education, supported with an educational grant from Novartis

Heart failure & SGLT2: with or without diabetes?

Event : ESC Congress 2018

  • Session : Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure (EBAC Accredited)
  • Speaker : JJV McMurray (Glasgow,GB)
  • Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Boehringer Ingelheim/Lilly

Heart Failure 2018 - From achievements to challenges.

Event : ESC Congress 2018

  • Session : The European Heart Journal’s advances in heart failure and valvular heart disease: the year in cardiology
  • Speaker : JJV McMurray (Glasgow,GB)
  • Joint with the European Heart Journal

Medical therapy

Event : Heart Failure 2018

  • Session : The year's best papers on heart failure
  • Speaker : JJV McMurray (Glasgow,GB)

My patient in NYHA functional class II is stable

Event : Heart Failure 2018

  • Session : Medical myths about heart failure and the facts behind them
  • Speaker : JJV McMurray (Glasgow,GB)

Opportunities versus obstacles - How to become a successful trialist?

Event : Heart Failure 2018

  • Session : Planning a career in cardiovascular medicine
  • Speaker : JJV McMurray (Glasgow,GB)

Panel discussion and audience Q&A.

Event : ESC Congress 2018

  • Session : Seize the moment to optimize treatment for each patient with heart failure: why, when, and how
  • Speaker : B Pieske (Berlin,DE), JJV McMurray (Glasgow,GB), R Wachter (Leipzig,DE), S Solomon (Boston,US)
  • Sponsored by Novartis Pharma AG

Pharmacologic glycaemic management and cardiovascular outcome trials

Event : Heart Failure 2018

  • Session : Diabetes and heart failure - A 21st century global challenge
  • Speaker : JJV McMurray (Glasgow,GB)

Seize the moment to optimize heart failure treatment: why, when, and how? Ask the experts.

Event : ESC Congress 2018

  • Session : Seize the moment to optimize heart failure treatment: why, when, and how? Ask the experts
  • Speaker : F Ruschitzka (Zurich,CH), JJV McMurray (Glasgow,GB), R Wachter (Leipzig,DE), S Solomon (Boston,US)
  • Sponsored by Novartis Pharma AG.

Summary and close - Seize the moment to optimize treatment for each patient with heart failure: why, when, and how.

Event : ESC Congress 2018

  • Session : Seize the moment to optimize treatment for each patient with heart failure: why, when, and how
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

Summary and close.

Event : Heart Failure 2018

  • Session : Resolving dilemmas in the treatment of heart failure
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis

The dilemma of treating perceived stable heart failure patients.

Event : Heart Failure 2018

  • Session : Resolving dilemmas in the treatment of heart failure
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis

Treatment of diabetes in heart failure - The future is sweet

Event : ESC Congress 2018

  • Session : Heart failure: the nemesis of Diabetes
  • Speaker : JJV McMurray (Glasgow,GB)

What action should we take when we see patients with perceived stable heart failure?

Event : ESC Congress 2018

  • Session : Seize the moment to optimize treatment for each patient with heart failure: why, when, and how
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

Your questions on dilemmas in the treatment of heart failure answered.

Event : Heart Failure 2018

  • Session : Your questions on dilemmas in the treatment of heart failure answered
  • Speaker : JJV McMurray (Glasgow,GB), CS Lam (Singapore,SG)
  • Sponsored by Novartis

Acute heart failure drug development: challenges and learnings.

Event : Heart Failure 2017

  • Session : Advancing acute heart failure treatment – quo vadis?
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis

Any place for novel heart failure therapies?

Event : Heart Failure 2017

  • Session : Getting the patient ready for discharge
  • Speaker : JJV McMurray (Glasgow,GB)

Discussion.

Event : Heart Failure 2017

  • Session : Heart failure, diabetes, and renal dysfunction: time for a more unified approach
  • Speaker : A Voors (Groningen,NL), M Cowie (London,GB), PH Groop (Hus,FI), JJV McMurray (Glasgow,GB)
  • Sponsored by PACE-CME -- Boehringer-Ingelheim/Lilly

Heart failure 2017 - An update.

Event : ESC Congress 2017

  • Session : The European Heart Journal's Year in Cardiology: heart failure and valvular heart disease
  • Speaker : JJV McMurray (Glasgow,GB)
  • Joint with the European Heart Journal

Improving outcomes in acute heart failure: quo vadis?

Event : Heart Failure 2017

  • Session : Advancing acute heart failure treatment – quo vadis?
  • Speaker : JJV McMurray (Glasgow,GB), A Mebazaa (Paris,FR), JR Teerlink (San Francisco,US)
  • Sponsored by Novartis

My heart failure patient in 2017: how did we do?

Event : ESC Congress 2017

  • Session : On the cutting edge of heart failure management: 2017
  • Speaker : JJV McMurray (Glasgow,GB)
  • Organised by Medscape Education, supported with an educational grant by Novartis

My heart failure patient in 2017: never too early and never stable!

Event : ESC Congress 2017

  • Session : On the cutting edge of heart failure management: 2017
  • Speaker : JJV McMurray (Glasgow,GB)
  • Organised by Medscape Education, supported with an educational grant by Novartis

New diabetes drugs and heart failure: what have we learnt?

Event : Heart Failure 2017

  • Session : Heart failure, diabetes, and renal dysfunction: time for a more unified approach
  • Speaker : JJV McMurray (Glasgow,GB)
  • Organised by Physicians Academy for Cardiovascular Education, supported by an unrestricted educational grant from Boehringer-Ingelheim and Lilly

One year after updating the heart failure guidelines – Has the management of patients with heart failure with reduced ejection fraction changed?

Event : Heart Failure 2017

  • Session : Contemporary management of patients with Heart Failure with reduced Ejection Fraction (HFrEF)
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis

Optimising treatment of heart failure – Where are we today?

Event : Heart Failure 2017

  • Session : Optimising treatment of heart failure – Where are we today?
  • Speaker : F Ruschitzka (Zurich,CH), JR Teerlink (San Francisco,US), JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis

Panel discussion - Managing heart failure in 2017.

Event : ESC Congress 2017

  • Session : Managing heart failure in 2017: the experts’ opinion
  • Speaker : M Komajda (Paris,FR), JJV McMurray (Glasgow,GB), D Atar (Oslo,NO), F Ruschitzka (Zurich,CH)
  • Organised by Medscape Education, supported with an educational grant by Novartis

Ready for prime time as first-line therapy? PRO.

Event : Heart Failure 2017

  • Session : LCZ 696 (Sacubitril/Valsartan)
  • Speaker : JJV McMurray (Glasgow,GB)

SGLT2 inhibition: the potential to change the heart failure landscape?

Event : ESC Congress 2017

  • Session : Challenging the current treatment paradigm - SGLT2 inhibition in heart failure (EBAC Accredited)
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by AstraZeneca

Summary and key learnings.

Event : Heart Failure 2017

  • Session : Advancing acute heart failure treatment – quo vadis?
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis

The ongoing problem of heart failure - Q&A.

Event : Heart Failure 2017

  • Session : Heart failure: what is the potential of SGLT2 inhibition?
  • Speaker : JJV McMurray (Glasgow,GB), S Williams (Manchester,GB)
  • Sponsored by AstraZeneca

The ongoing problem of heart failure.

Event : Heart Failure 2017

  • Session : Heart failure: what is the potential of SGLT2 inhibition?
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by AstraZeneca

Welcome and introduction.

Event : Heart Failure 2017

  • Session : Advancing acute heart failure treatment – quo vadis?
  • Speaker : JJV McMurray (Glasgow,GB), A Mebazaa (Paris,FR)
  • Sponsored by Novartis

Welcome and introduction.

Event : Heart Failure 2017

  • Session : Contemporary management of patients with Heart Failure with reduced Ejection Fraction (HFrEF)
  • Speaker : JJV McMurray (Glasgow,GB), F Zannad (Vandoeuvre,FR)
  • Sponsored by Novartis

Will ACE inhibitors be abandoned in the treatment of HFrEF?

Event : ESC Congress 2017

  • Session : The future therapy of heart failure: shall we find the answers in the crystal ball?
  • Speaker : JJV McMurray (Glasgow,GB)

ACE - inhibitors should be replaced by LCZ696 as first line therapy for heart failure - PRO

Event : ESC Congress 2016

  • Session : Controversies in heart failure
  • Speaker : JJV McMurray (Glasgow,GB)

Ask the experts: your questions on optimizing heart failure management and the future of new treatments answered.

Event : Heart Failure 2016

  • Session : Ask the experts: your questions on optimizing heart failure management and the future of new treatments answered
  • Speaker : JJV McMurray (Glasgow,GB), B Pieske (Berlin,DE), F Ruschitzka (Zurich,CH), M Senni (Bergamo,IT)
  • Sponsored by Novartis Pharma AG

Drugs on the horizon.

Event : Heart Failure 2016

  • Session : Novel heart failure therapies
  • Speaker : JJV McMurray (Glasgow,GB)

Heart failure & diabetes: SGLT2 inhibition, a paradigm shift?

Event : ESC Congress 2016

  • Session : SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?
  • Speaker : JJV McMurray (Glasgow,GB)
  • Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly

Heart failure 2016 - An update

Event : ESC Congress 2016

  • Session : The European Heart Journal's Year in Cardiology: heart failure and valvular heart disease
  • Speaker : JJV McMurray (Glasgow,GB)
  • Joint with the European Heart Journal

Improving heart failure outcomes: what is the role and future of new versus current treatments?

Event : Heart Failure 2016

  • Session : Stepping up to improve outcomes in heart failure: the role and future of new versus current treatments
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

Interactive discussion: what are the implications of SGLT2 inhibition in HF patients with diabetes?

Event : ESC Congress 2016

  • Session : SGLT2 inhibition in diabetes and heart failure: discuss the evidence
  • Speaker : D Fitchett (Toronto,CA), JJV McMurray (Glasgow,GB)
  • Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly

Optimizing treatment for any symptomatic heart failure with reduced ejection fraction patients.

Event : ESC Congress 2016

  • Session : Optimizing outcomes in patients with heart failure with reduced ejection fraction: evidence and clinical experience sharing
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

Panel discussion - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

Event : ESC Congress 2016

  • Session : SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?
  • Speaker : D Fitchett (Toronto,CA), JJV McMurray (Glasgow,GB)
  • Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly

Prevention of heart failure in hypertension - Past and future treatments

Event : ESC Congress 2016

  • Session : Transition from hypertension to heart failure
  • Speaker : JJV McMurray (Glasgow,GB)

SGLT2 inhibition: exploring the evidence in diabetes and heart failure.

Event : ESC Congress 2016

  • Session : SGLT2 inhibition in diabetes and heart failure: discuss the evidence
  • Speaker : JJV McMurray (Glasgow,GB)
  • Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly

Summary and key learning points from the entire symposium topics.

Event : ESC Congress 2016

  • Session : Optimizing outcomes in patients with heart failure with reduced ejection fraction: evidence and clinical experience sharing
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

The cost-effectiveness of sacubitril/valsartan in chronic heart failure with reduced ejection fraction

Event : Heart Failure 2016

  • Session : Basic Science: Chronic heart failure
  • Speaker : JJV McMurray (Glasgow,GB)

The drug and the PARADIGM-HF trial.

Event : Heart Failure 2016

  • Session : What a busy clinician needs to know about LCZ696 for heart failure
  • Speaker : JJV McMurray (Glasgow,GB)

Welcome and introduction.

Event : ESC Congress 2016

  • Session : Optimizing outcomes in patients with heart failure with reduced ejection fraction: evidence and clinical experience sharing
  • Speaker : JJV McMurray (Glasgow,GB), M Senni (Bergamo,IT)
  • Sponsored by Novartis Pharma AG

Welcome and introduction.

Event : Heart Failure 2016

  • Session : Stepping up to improve outcomes in heart failure: the role and future of new versus current treatments
  • Speaker : AP Maggioni (Milano,IT), JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

A case of HF management today: can we do better for our patients?

Event : ESC Congress 2015

  • Session : Where are we with current Heart Failure (HF) management systems, structure and science?
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Medscape Cardiology / theheart.org

ALBATROSS: Discussant review.

Event : ESC Congress 2015

  • Session : Hot Line I - Acute myocardial infarction
  • Speaker : JJV McMurray (Glasgow,GB)

All-cause and cardiovascular death.

Event : Heart Failure 2015

  • Session : Results of PARADIGM-HF: a closer look
  • Speaker : JJV McMurray (Glasgow,GB)

Angiotensin/Neprolysin Inhibition in heart failure — Represented in NEJM by the PARADIGM-HF trial

Event : ESC Congress 2015

  • Session : Highlights from the New England Journal of Medicine: editors’ choice
  • Speaker : JJV McMurray (Glasgow,GB)
  • ESC and the NEJM

ARNIs (LCZ696). Ready for prime time - PRO.

Event : Heart Failure 2015

  • Session : Hot issues in heart failure
  • Speaker : JJV McMurray (Glasgow,GB)

ARNIs: The new frontier.

Event : Heart Failure 2015

  • Session : The success of neurohormonal blockade: looking back – looking forward
  • Speaker : JJV McMurray (Glasgow,GB)

Chronic heart failure.

Event : Heart Failure 2015

  • Session : The European Heart Journal’s / European Journal of Heart Failure’s year in Cardiology
  • Speaker : JJV McMurray (Glasgow,GB)

Discussion, questions and answers.

Event : Heart Failure 2015

  • Session : Ask the experts: your questions answered on HF management and multidisciplinary approaches
  • Speaker : JJV McMurray (Glasgow,GB), A Voors (Groningen,NL), A Mebazaa (Paris,FR), J Diez Martinez (Pamplona,ES), T McDonagh (London,GB), H Bueno (Madrid,ES), A Stromberg (Linkoping,SE)
  • Sponsored by Novartis Pharma

Discussion: AUGMENT-HF.

Event : Heart Failure 2015

  • Session : Late Breaking Trials III: Devices and interventions
  • Speaker : JJV McMurray (Glasgow,GB)

Drugs for chronic heart failure.

Event : ESC Congress 2015

  • Session : The ESC/HFA Guidelines on acute and chronic heart failure
  • Speaker : JJV McMurray (Glasgow,GB)

Guidelines and unanswered questions.

Event : Heart Failure 2015

  • Session : Antithrombotics in heart failure: the controversy continues
  • Speaker : JJV McMurray (Glasgow,GB)

Heart Failure 2015 – New drugs on the horizon.

Event : ESC Congress 2015

  • Session : The European Heart Journal's year in cardiology: heart failure and valvular heart disease
  • Speaker : JJV McMurray (Glasgow,GB)

Is LCZ 696 widely applicable therapy for patients with heart failure?

Event : Heart Failure 2015

  • Session : Controversial issues in drug therapy
  • Speaker : JJV McMurray (Glasgow,GB)

New therapies for chronic heart failure.

Event : Heart Failure 2015

  • Session : Taking strides to improve outcomes in heart failure: today’s and tomorrow’s approaches
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma

Panel Discussion - New paradigms in heart failure: RAAS inhibition and the management of hyperkalemia.

Event : ESC Congress 2015

  • Session : New paradigms in heart failure: RAAS inhibition and the management of hyperkalemia
  • Speaker : JJV McMurray (Glasgow,GB), F Zannad (Vandoeuvre,FR), I Pina (Detroit,US)
  • Sponsored by ZS Pharma, Inc.

Paradigm shifts in the pharmacological management of heart failure.

Event : ESC Congress 2015

  • Session : New paradigms in heart failure: RAAS inhibition and the management of hyperkalemia
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by ZS Pharma, Inc.

Questions and answers - New paradigms in heart failure: RAAS inhibition and the management of hyperkalemia.

Event : ESC Congress 2015

  • Session : New paradigms in heart failure: RAAS inhibition and the management of hyperkalemia
  • Speaker : JJV McMurray (Glasgow,GB), F Zannad (Vandoeuvre,FR), I Pina (Detroit,US)
  • Sponsored by ZS Pharma, Inc.

Welcome and introduction.

Event : Heart Failure 2015

  • Session : The failing heart: a team approach to address unmet needs for better patient care
  • Speaker : JJV McMurray (Glasgow,GB), A Voors (Groningen,NL)
  • Sponsored by Novartis Pharma

Welcome and introductions - New paradigms in heart failure: RAAS inhibition and the management of hyperkalemia.

Event : ESC Congress 2015

  • Session : New paradigms in heart failure: RAAS inhibition and the management of hyperkalemia
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by ZS Pharma, Inc.

Welcome/introduction and the journey through HF.

Event : Heart Failure 2015

  • Session : Taking strides to improve outcomes in heart failure: today’s and tomorrow’s approaches
  • Speaker : JJV McMurray (Glasgow,GB), A Voors (Groningen,NL)
  • Sponsored by Novartis Pharma

Wrap up and closing remarks - Where are we with current Heart Failure (HF) management systems, structure and science?

Event : ESC Congress 2015

  • Session : Where are we with current Heart Failure (HF) management systems, structure and science?
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Medscape Cardiology / theheart.org

Ask the faculty – Q&A.

Event : ESC Congress 2014

  • Session : Heart failure management: additional considerations for addressing patients' needs
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

Chronic heart failure: can we change the course of the disease?

Event : ESC Congress 2014

  • Session : The heart failure journey: optimizing treatment to improve outcomes
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

Chronic heart failure: what do the Guidelines say?

Event : ESC Congress 2014

  • Session : Drug therapy: when guidelines do not have all the answers
  • Speaker : JJV McMurray (Glasgow,GB)

Discussing heart failure management: faculty perspectives.

Event : ESC Congress 2014

  • Session : Heart failure management: additional considerations for addressing patients' needs
  • Speaker : JJV McMurray (Glasgow,GB), A Voors (Groningen,NL)
  • Sponsored by Novartis Pharma AG

Guidelines on heart failure in daily practice: conclusion and take home message.

Event : ESC Congress 2014

  • Session : Guidelines on heart failure in daily practice
  • Speaker : JJV McMurray (Glasgow,GB)

Heart failure 2014.

Event : ESC Congress 2014

  • Session : The European Heart Journal’s Year in Cardiology: heart failure and valvular heart disease
  • Speaker : JJV McMurray (Glasgow,GB)

Panel.

Event : ESC Congress 2014

  • Session : PARADIGM-HF: The experts' discussion
  • Speaker : JJV McMurray (Glasgow,GB), M Packer (Dallas,US), K Fox (Edinburgh,GB), M Komajda (Paris,FR)

Sodium restriction for chronic heart failure patients is useful. CONTRA.

Event : ESC Congress 2014

  • Session : Transatlantic differences in heart failure management
  • Speaker : JJV McMurray (Glasgow,GB)

Sodium restriction for chronic heart failure patients is useful. REBUTTAL CONTRA.

Event : ESC Congress 2014

  • Session : Transatlantic differences in heart failure management
  • Speaker : JJV McMurray (Glasgow,GB)

The failing heart with reduced ejection fraction: managing a heart with primarily systolic dysfunction.

Event : ESC Congress 2014

  • Session : Recent advances in our understanding of the failing heart: what have we learned, what needs to be done?
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

Acute heart failure and readmissions: the role of kidney dysfunction.

Event : ESC Congress 2013

  • Session : Treating acute and advanced heart failure: what clinicians need to know in 2013
  • Speaker : JJV McMurray (Glasgow,GB)

Heart failure: solving difficult problems - Take home message & what do the guidelines say?

Event : ESC Congress 2013

  • Session : Heart failure: solving difficult problems
  • Speaker : JJV McMurray (Glasgow,GB)

Panel discussion: iron deficiency in heart failure – From evidence to practice.

Event : ESC Congress 2013

  • Session : Iron deficiency in heart failure – From evidence to practice
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Vifor Pharma

Pharmacological management.

Event : ESC Congress 2013

  • Session : Challenges in heart failure with preserved ejection fraction
  • Speaker : JJV McMurray (Glasgow,GB)

Plotting a new course to improved chronic heart failure management.

Event : ESC Congress 2013

  • Session : Embarking on the voyage to successful heart failure management: the many roles of the cardiologist
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are